Weight gain from novel antipsychotic drugs: Need for action

General Hospital Psychiatry

Volumn 22, Issue 4, 2000, Pages 224-235

  Green, Alan I ^a   Patel, Jayendra K ^a,b   Goisman, Robert M ^a,b   Allison, David B ^c   Blackburn, George ^b,c  

^a MASSACHUSETTS MENTAL HEALTH CENTER   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; NEUROLEPTIC AGENT;

BEHAVIOR THERAPY; BODY WEIGHT; CARDIOVASCULAR DISEASE; GLUCOSE INTOLERANCE; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; SCHIZOPHRENIA; SOCIAL ADAPTATION; WEIGHT GAIN;

EID: 0034622243     PISSN: 01638343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-8343(00)00081-5     Document Type: Article

References (165)

1. Andreasen N.C. Understanding the causes of schizophrenia. N Eng J Med. 340:(8):1999;645-647.
2. Ho B.C., Andreasen N., Flaum M. Dependence on public financial support early in the course of schizophrenia. Psychiatr Serv. 48:1997;948-950.
3. Cohen L.J., Test M.A., Brown R.L. Suicide and schizophrenia data from a prospective community treatment study . Am J Psychiatry. 147:1990;602-607.
4. Axelsson R., Lagerkvist-Briggs M. Factors predicting suicide in psychotic patients. Eur Arch Psychiatr Clin Neurosci. 241:1992;259-266.
5. Bernstein J.G. Induction of obesity by psychotropic drugs. Ann NY Acad Sci. 499:1987;203-215.
6. Allison D.B., Fontaine K.R., Heo M., Mentore J.L., Cappelleri J.C., Chandler L.P., Weiden P.J., Cheskin L.J. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry. 60:1999;215-220.
7. Beasley CM: Safety of olanzapine. J Clin Psychiatry Monograph 1997a;15(2):19-21, 1997a.
8. Stanton J.M. Weight gain associated with neuroleptic medication a review . Schizophr Bull. 21:1995;463-472.
9. Kando J.C., Shepski J.C., Satterlee W., Patel J.K., Reams S.G., Green A.I. Olanzapine a new antipsychotic agent with efficacy in the management of schizophrenia . Ann Pharmacother. 31:1997;1325-1334.
10. Umbricht D.S., Pollack S., Kane J.M. Clozapine and weight gain. J Clin Psychiatry. 55:(suppl B):1994;157-160.
11. Masand PS, Blackburn GL, Ganguli R, Goldman LS, Gorman J, Greenberg I, Kawachi I, Perkins DO, Sachs GS: Weight gain associated with the use of antipsychotic medications. J Clin Psychiatry Audiograph Series 1999;2.
12. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. Obes Res. 6:(suppl 2):1998;51S-209S.
13. Pijl H., Meinders A.E. Body weight change as an adverse effect of drug treatment. Drug Safety. 14:1996;329-342.
14. Andreasen N.C., Paradios S., O'Leary D.S. "Cognitive dysmetria" as an integrative theory of schizophrenia a dysfunction in cortical-subcortical-cerebellar circuitry? Schizophr Bull. 24:1998;203-218.
15. Woods B.T. Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenic mechanism. Am J Psychiatry. 155:1998;1661-1670.
16. Jones P., Murray R.M. The genetics of schizophrenia is the genetics of neurodevelopment. Br J Psychiatry. 158:1991;615-623.
17. Armstrong E., Schleicher A., Omran H., Curtis M., Zilles K. The ontogeny of human gyrification. Cereb Cortex. 5:1995;56-63.
18. McGlashan T.H. A selective review of recent North American long-term follow-up studies of schizophrenia. Schizophr Bull. 14:1988;514-542.
19. Eaton W.W., Mortensen P.B., Herrman H., Freeman H., Bilker W., Burgess P., Wooff K. Long-term course of hospitalization for schizophrenia I. Risk for rehospitalization . Schizophr Bull. 18:1992;217-228.
20. Kenny J., Meltzer H.Y. Attention of higher cortical functions in schizophrenia. J Neuropsychiatr Clin Neurosci. 3:1991;269-275.
21. Saykin A.J., Gur R.C., Gur R.E., Mozley D., Mozley L.H., Resnick S.M., Kester D.B., Stafiniak P. Neuropsychological function in schizophrenia Selective impairment in memory and learning . Arch Gen Psychiatry. 48:1991;618-624.
22. Seidman L.J., Oscar-Berman M., Kalinowski A.G., Ajilor O., Kremen W.S., Faraone S.V., Tsuang M.T. Experimental and clinical neuropsychological measures of prefrontal dysfunction in schizophrenia. Neuropsychology. 9:1995;481-490.
23. Bellack A.S. Cognitive rehabilitation for schizophrenia is it possible? Is it necessary? Schizophr Bull. 18:1992;43-49.
24. Jaeger J., Berns S., Tigner A., Douglas E. Remediation of neuropsychological deficits in psychiatric populations rationale and methodological considerations . Psychopharmacol Bull. 28:1992;367-390.
25. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., Goodwin F.K. Comorbidity of mental disorders with alcohol and other drug abuse. JAMA. 264:1990;2511-2518.
26. Green A.I., Zimmet S.V., Strous R.D., Schildkraut J.J. Substance use disorder and schizophrenia do patients with schizophrenia have a reward deficiency syndrome that can be ameliorated by clozapine? Harv Rev Psychiatry. 6:1999;289-296.
27. Brown S. Excess mortality of schizophrenia a meta-analysis . Br J Psychiatry. 171:1997;502-508.
28. Tsuang M.T. Suicide in schizophrenics, manics, depressives, and surgical controls a comparison with general population suicide mortality . Arch Gen Psychiatry. 35:1978;153-155.
29. Meltzer H.Y., Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia impact on Risk-Benefit assessment . Am J Psychiatry. 152:1995;183-189.
30. Davis J.M. Overview maintenance therapy in psychiatry, I: schizophrenia . Am J Psychiatry. 132:1975;1237-1245.
31. Klein D.F., Davis J.M. Diagnosis and Drug Treatment of Psychiatric Disorders. 1969;Krieger, Huntington, NY.
32. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 151:1994;825-835.
33. Meltzer H.Y., Lee M.A., Ranjan R. Recent advances in the pharmacotherapy of schizophrenia. Acta Psychiatr Scand Suppl. 384:1994;95-101.
34. Kane J: Olanzapine in the long-term treatment of schizophrenia. Br J Psychiatry 1999;174(suppl 37):26-29.
35. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry. 45:1988;789-796.
36. Jibson M.D.E., Tandon R. A summary of research findings on the new antipsychotic drugs. Essent Psychopharmacol. 1:1996;27-37.
37. Beasley CM, Tollefson GD, Tran PV: Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry 1997c;58(suppl 10):7-12.
38. Small J.G., Hirsch S.R., Arvanitis L.A., Miller B.G., Link C.G. Quetiapine inpatients with schizophrenia a high and low dose double-blind comparison with placebo . Arch Gen Psychiatry. 54:1997;549-557.
39. Bymaster F., Perry K.W., Nelson D.L., Wong D.T., Rasmussen K., Moore N.A., Calligaro D.O. Olanzapine a basic science update . Br J Psychiatry. 174:(suppl 17):1999;36-40.
40. Breier A., Buchanan R.W., Kirkpatrick B., Davis R.O., Irish D., Summerfelt A., Carpenter W.T. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 151:1994;20-26.
41. Green A.I., Schilddraut J.J. Should clozapine be a first-line treatment for schizophrenia the rationale for a double-blind clinical trial in first-episode patients . Harv Rev Psychiatry. 3:1995;1-9.
42. Stone W.S., Seidman L.J., Kalinowski A., Shagrin B., Patel J.K., Shafa R., Canuso C., Schildkraut J.J., Green A.I. Effects of clozapine on cognitive functioning in treatment-refractory schizophrenia. Schizophrenia Res. 24:1997;188.
43. Breier A. Cognitive deficit in schizophrenia and its neurochemical basis. Br J Psych. 174:(suppl 37):1999;16-18.
44. Lindstrom L.H. The effect of long-term treatment with clozapine in schizophrenia. Acta Psychiatr Scand. 77:1988;524-529.
45. Meltzer H.Y. Dimensions of outcome with clozapine. Br J Psychiatry. 160:1992;46-53.
46. Albanese M.J., Khantzian E.J., Murphy S.L., Green A.I. Decreased substance use in chronically psychotic patients treated with clozapine. Am J Psychiatry. 151:1994;780-781.
47. Drake RE, Xie H, McHugo GJ, Green AI: The effects of clozapine on alcohol and drug use disorders among schizophrenic patients. Schizophr Bull, in press.
48. Weiden P., Scheifler P., Diamond R., Ross R. Breakthroughs in Antipsychotic Medications A Guide for Consumers, Families, and Clinicians . 1999;Norton, New York.
49. Gerlach J., Peacock L. Motor and mental side effects of clozapine. J Clin Psychiatry. 55:(suppl B):1994;107-109.
50. Kerwin R.W. The new atypical antipsychotics a lack of extrapyramidal side-effects and new routes in schizophrenia research . Br J Psychiatry. 164:1994;141-148.
51. McGlashan T.H. Early detection and intervention in schizophrenia research. Schizophrenia Bull. 22:1996;327-345.
52. Post F. Body-weight changes in psychiatric illness a critical survey of the literature . J Psychosom Res. 1:1956;219-226.
53. Amdisen A. Drug-produced obesity experiences with chlorpromazine, perphenazine, and clopenthixol . Dan Med Bull. 11:1964;182-189.
54. Caffey E.M. Experience with large scale interhospital co-operative research in chemotherapy. Am J Psychiatry. 117:1971;713.
55. Doss F.W. The effect of antipsychotic drugs on body weight a retrospective review . J Clin Psychiatry. 40:1979;528-530.
56. U.S. Department of Health and Human Services: 1989 National Health Interview Survey. CD-ROM Series 1993;10(3).
57. Silverstone T., Smith G., Goodall E. Prevalence of obesity in patients receiving depot antipsychotics. Br J Psychol. 153:1988;214-217.
58. Stedman T., Welham J. The distribution of adipose tissue in female inpatients receiving psychotropic drugs. Br J Psychiatry. 162:1993;249-250.
59. Kendrick T. Cardiovascular and respiratory risk factors and symptoms among general practice patients with long-term mental illness. Br J Psychiatry. 169:1996;733-739.
60. Centorrino F., Baldessarini R.J., Kando J.C., Frankenburg F.R., Vopicelli S.A., Flood J.G. Clozapine and metabolites concentrations in serum and clinical findings suring treatment of chronically psychotic patients . J Clin Psychopharmacol. 14:1994;119-125.
61. Wirshing D.A., Spellberg B.J., Erhart S.M., Marder S.R., Wirshing W.C. Novel antipsychotics and new onset diabetes. Biol Psychiatry. 44:1998;778-783.
62. Leadbetter R., Shutty M., Pavalonis D., Vieweg V., Higgins P., Downs M. Clozapine-induced weight gain prevalence and clinical relevance . Am J Psychiatry. 149:1992;68-72.
63. Casey D. Side effect profiles of new antipsychotic agents. J Clin Psychiatry. 57:(suppl 11):1996;40-45.
64. Kane J.M. What are the therapeutic needs in schizophrenia and how are they satisfied by new antipsychotics? Int Clin Psychopharmacol. 12:(suppl 2):1997;S3-S6.
65. Beasley C.M., Tollefson G.D., Tran P.V. Safety of olanzapine. J Clin Psychiatry. 58:(suppl 10):1997;13-17.
66. Bromel T., Blum W.F., Ziegler A., Schulz E., Bender M., Fleischhaker C., Remschmidt H., Krieg J.C., Hegebrand J. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry. 3:1998;76-80.
67. Allison D.B., Mentore J.M., Heo M., Chandler L., Cappelleri J.C., Infante M., Weiden P. Antipsychotic-induced weight gain a comprehensive research synthesis . Am J Psychiatry. 156:(11):1999;1686-1696.
68. Sussman N., Ginsberg D. Effects of psychotropic drugs on weight. Psychiatric Ann. 29:1999;580-594.
69. Lamberti J.S., Bellnier T., Schwarzkopf S.B. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry. 149:1992;689-690.
70. Bustillo J.R., Buchanan R.W., Irish D., Breier A. Differential effect of clozapine on weight a controlled study . Am J Psychiatry. 153:1996;817-819.
71. Wirshing D.A., Wirshing W.C., Kysar L., et al. Novel antipsychotics comparison of weight gain liabilities . J Clin Psychiatry. 60:1999;358-363.
72. Kelly D.L., Conley R.R., Love R.C., et al. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol. 8:1998;151-159.
73. McDougle C.J., Holmes J.P., Carlson D.C., et al. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psych. 55:1998;633-641.
74. Young J.L., Zonona H.U., Shepler L. Medication compliance in schizophrenia codification and update . Bull Am Acad Psychiatry Law. 14:1986;105-122.
75. Robinson D., Woerner M.G., Alvir J., Bildner R., Goldman R., Geisler S., Koreen A., Sheitman B., Chakos M., Mayerhoff D., Lieberman J.A. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 56:1999;241-247.
76. Wyatt R.J. Neuroleptics and the natural course of schizophrenia. Schizophrenia Bull. 17:1991;325-351.
77. Lieberman J.A. Atypical antipsychotic drugs as a first-line treatment of schizophrenia a rationale and hypothesis . J Clin Psychiatry. 57:(suppl 11):1996;68-71.
78. Robinson R.G. Measurement of appetite disturbances in psychiatric disorders. J Psychiatr Res. 12:1975;59-68.
79. Cookson J.C. Side effects during long-term treatment with a depot antipsychotic medication. Clin Neuropharm. 14:(suppl 2):1991;S24-S32.
80. Flegel K.M., Carroll M.D., Kuczmarski R.J., Johnson C.L. Overweight and obesity in the United States prevalence and trends, 1960-1994 . Int J Obes Relat Metab Disord. 22:1998;39-47.
81. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. 1998;U.S. Department of Health and Human Services, Bethesda, MD.
82. Physical Activity and Health A Report of the Surgeon General . 1996;U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Division of Nutrition and Physical Activity, Atlanta, GA.
83. Shape Up America! and the American Obesity Association: Guidance for Treatment of Adult Obesity. Bethesda, MD, 1996.
84. Mukherjee S., Decina P., Bocola V., Saraceni F., Scapicchio P.L. Diabetes mellitus in schizophrenic patients. Compr Psychiatry. 37:1996;68-73.
85. McKee H.A., D'Arcy P.F., Wilson P.J. Diabetes and schizophrenia - a preliminary study. J Clin Hosp Pharm. 11:1986;297-299.
86. Tsuang M.T., Perkins K., Simpson J.C. Physical diseases in schizophrenia and affective disorder. J Clin Psychiatry. 44:1993;42-46.
87. Brambilla F., Guastalla A., Guerrini A., Riggi F., Rovere C., Zanoboni A., Zanoboni-Muciaccia W. Glucose-insulin metabolism in chronic schizophrenia. Dis Nerv Syst. 37:1976;98-103.
88. Williamson D. Descriptive epidemiology of body weight and weight change in U.S. adults. Ann Intern Med. 119:1993;646-649.
89. Gill T.P. Key issues in the prevention of obesity. Br Med Bull. 53:1997;359-388.
90. Lee I.M., Paffenbarger R.S. Jr. Change in body weight and longevity. JAMA. 268:1992;2045-2049.
91. Rimm E.B., Stampfer M.J., Giovannucci E., Ascherio A., Spiegelman D., Coldity G.A., Willett W.C. Body size and fat distribution as markers of coronary heart disease among young and older men. Am J Epidemiol. 141:1995;1117-1127.
92. Chan J.M., Rimm E.B., Colditz G.A., Stampfer M.J., Willett W.C. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 17:1994;961-969.
93. Colditz G.A., Willett W.C., Rotnitzky A., Manson J.E. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 122:1995;481-486.
94. Liese A., Mayer-Davis E., Haffner S.M. Development of the multiple metabolic syndrome an epidemiological perspective . Epidemiol Rev. 20:1998;157-172.
95. Maggio C., Pi-Sunyer F.X. The prevention and treatment of obesity. Application to type 2 diabetes. Diabetes Care. 20:1997;1744-1766.
96. Blackburn G.L. Effect of degree of weight loss on health benefits. Obes Res. 3:(suppl 2):1995;211S-216S.
97. Kanders B.S., Blackburn G.L. Health consequences of therapeutic weight loss reducing primary risk factors . Wadden T.A., Van Itallie T.B. The Treatment of the Seriously Obese Patient. 1992;213-230 Guilford Press, New York.
98. Daly P.A., Solomon C.G., Manson J.E. Risk Modification in the Obese Patient. 1996;Oxford University Press, New York.
99. Ferrannini E., Haffner S.M., Mitchell B.D., Stern M.P. Hyperinsulinaemia the key features of a cardiovascular and metabolic syndrome . Diabetologia. 34:1991;416-422.
100. Ferrannini E. Syndrome X. Horm Res. 39:(suppl 3):1993;107-111.
101. Reaven G.M. Role of insulin resistance in human disease (syndrome X) an expanded definition . Annu Rev Med. 44:1993;121-131.
102. Mantzoros C., Flier J. Insulin resistance the clinical spectrum . Adv Endocrinol Metab. 6:1995;193-232.
103. Everson S., Goldberg D.E., Helmrich S.P., Lakka T.A., Lynch J.W., Kaplan G.A., Solonen J.T. Weight gain and the risk of developing insulin resistance syndrome. Diabetes Care. 21:1998;1637-1643.
104. Haffner S., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med. 339:1998;229-234.
105. Eckel R.H., Krauss R.M. American Heart Association call to action obesity as a major risk factor for coronary heart disease . Circulation. 97:1998;2099-2100.
106. Schultz S.K., Arndt S., Ho B.C., Oliver S.E., Andreasen N.C. Impaired glucose tolerance and abnormal movements in patients with schizophrenia. Am J Psychiatry. 156:1999;640-642.
107. Glenny A.M., O'Meara S., Melville A., Sheldon T.A., Wilson C. The treatment and prevention of obesity. Int J Obes. 21:1997;715-737.
108. Kramer F.M., Jeffery R.W., Snell M.K., Forster J.L. Maintenance of successful weight loss over 1 year effects of financial contracts for weight maintenance or participation in skills training . Behaviour Therapy. 17:1986;295-301.
109. Ditschuneit H.H., Flechtner-Mors M., Adler G. Metabolic and weight loss effects of long-term dietary intervention in obese patients. Am J Clin Nutr. 69:1999;198-204.
110. Pronk N.P., Wing R.R. Physical activity and long-term maintenance of weight loss. Obes Res. 2:1994;587-599.
111. Jeffery R.W., Wing R.R., Thorson C., Burton L.R. Use of personal trainers and financial incentives to increase exercise in a behavioral weight loss program. J Consult Clinl Psychol. 66:1998;777-783.
112. Blackburn GL, Waugh R, Elashoff R, Johnson T, BALI study group: Predictors of successful change in behavior in the Black American Lifestyle Intervention (BALI) Study. Int J Obes 22(suppl):S287, 1998.
113. Baum J.G., Clark H.B., Sandler J. Preventing relapse in obesity through post-treatment maintenance systems comparing the relative efficacy of two levels of therapist support . J Behavioral Med. 14:1991;287-302.
114. Miura J., Arai K., Tsukahara S., Ohno M., Ikeda Y. The long term effectiveness of combined therapy by behavior modification and very low calorie diet a two-year follow-up . Inter J Obes. 13:(suppl):1989;73-77.
115. Wadden T.A., Berkowitz R.I., Vogt R.A., Steen S.N., Stunkard A.J., Foster G.D. Lifestyle modifications in the pharmacologic treatment of obesity a pilot investigation of a primary care approach . Obes Res. 5:1997;218-226.
116. Rotatori A.F., Fox R., Wicks A. Weight loss with psychiatric residents in a behavioral self-control program. Psychological Rep. 46:1980;483-486.
117. Ferster C.B., Nurenberger J.I., Levitt E.B. The control of eating. J Mathetics. 1:1962;87-109.
118. Knox J.M. A study of weight reducing diets in psychiatric in-patients. Br J Psychia. 136:1980;287-289.
119. Klien B., Steel R.I., Simon W.E., Primavera L.H. Reinforcement and weight loss in schizophrenics. Psycol Rep. 30:1972;581-582.
120. Stuart R.B. Behavioral control of overeating. Behav Res Ther. 5:1967;357.
121. Paul G., Lentz R.J. Psychosocial Treatment of Chronic Mental Patients Milieu Versus Social Learning Programs . 1977;Harvard University Press, Cambridge, MA.
122. Menditto A.A., Beck N.C., Stove P., Fisher J.A., Stacy N., Logue M.B., Baldwin L.J. Effectiveness of clozapine and a social learning program for severely disabled psychiatric inpatients. Psychiatric Services. 47:1996;46-51.
123. Smith T.E., Hull J.W., MacKain S.J., Wallace C.J., Rattenni L.A., Goodman M., Anthony D.A., Kentros M.K. Training hospitalized patients with schizophrenia in community reintegration skills. Psychiatric Services. 47:1996;1099-1103.
124. Goisman R.M. Social skills training, atypical neuroleptics and treatment-refractory psychosis. Int Rev Psychiatry. 10:1998;84-89.
125. Liberman R.P., Van Putten T., Marshall B.D. Jr, Mintz J., Bowen L., Kuehnel T.G., Aravagiri M., Marder S.R. Optimal drug and behavior therapy for treatment-refractory schizophrenic patients. Am J Psychiatry. 151:1994;756-759.
126. Psychiatric Rehabilitation Consultants: Social and independent living skills: symposium management module trainer's manual. 1988.
127. Psychiatric Rehabilitation Consultants: Social and independent living skills: the community re-entry program trainer's manual. 1995.
128. Liberman R.P., Wallace C.J., Blackwell G., Eckman T.A., Vaccaro J.V., Kuehnel T.G. Innovations in skills training for the seriously mentally ill the UCLA social and independent living skills modules . Innovations Res. 2:1993;43-60.
129. Dengel D.R., Pratley R.E., Hagberg J.M., Rogus E.M., Goldberg A.P. Improvements in blood pressure, glucose metabolism and lipoprotein lipids after aerobic exercise plus weight loss in obese, hypertensive middle-aged men. Metabolism. 47:1998;1075-1082.
130. DiPietro L., Seeman T.E., Stachenfeld N.S., Katz L.D., Nadel E.R. Moderate-intensity aerobic training improves glucose tolerance in aging independent of abdominal adiposity. J Am Geriatr Soc. 46:1998;875-879.
131. Segal K.R., Edano A., Abalos A., Albu J., Blando L., Tomas M.B., Pi-Sunyer F.X. Effect of exercise training on insulin sensitivity and glucose metabolism in lean, obese, and diabetic men. J Appl Physiol. 71:1991;2402-2411.
132. Pratt M. Benefits of lifestyle activity versus structured exercise. JAMA. 281:1999;375-376.
133. Sallis J.F., Bauman A., Pratt M. Environmental and policy interventions to promote physical activity. Am J Prev Med. 15:1998;379-397.
134. Allison D.B. If we live in a deterministic world, why can't we predict treatment outcome? In DB Allison, F Pi-Sunyer (eds), Obesity Treatment Establishing Goals, Improving Outcomes, and Reviewing the Research Agenda . 1995;Plenum Press, Proceedings of a NATO Advanced Research Workshop, New York.
135. Yanovski S.Z. National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA. 276:1996;1907-1915.
136. Goldstein D.J. Beneficial health effects of modest weight loss. Int J Obes. 16:1992;379-415.
137. Atkinson R.L., Hubbard V.S. Report on the NIH Workshop on Pharmacologic Treatment of Obesity. Am J Clin Nutr. 60:1994;153-156.
138. Weintraub M., Taves D.R., Hasday J.D., Mushlin A.I., Lockwood D.H. Determinants of response to anorexiants. Clin Pharmacol Ther. 30:1981;528-533.
139. Davidson M.H., Hauptman J., DiGirolamo M., Foreyt J.P., Halsted C.H., Heber D., Heimburger D.C., Lucas C.P., Robbins D.C., Chung J., Heymsfield S.B. Weight control and risk factor reduction in obese subjects treated with orlistat. JAMA. 281:1999;235-242.
140. Hollander P.A., Elbein S.C., Hirsch I.B., Kelley D., McGill J., Taylor T., Weiss S.R., Crockett S.E., Kaplan R.A., Comstock J., Lucas C.P., Lodewick P.A., Canovatchel W., Chung J., Hauptman J. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 2-year randomized double-blind study. Diabetes Care. 21:1998;1288-1294.
141. Bray G.A., Blackburn G.L., Ferguson J.M., Greenway F.L., Jain A.K., Mendel C.M., Ryan D.H., Schwartz S.L., Scheinbaum M.L., Seaton T.B. Sibutramine produces dose-related weight loss. Obes Res. 7:1999;189-198.
142. Cleare A.J. Phentermine, psychosis, and family history. J Clin Psychopharmacol. 16:1996;470-471.
143. Devan G.S. Phentermine and psychosis. Br J Psychiatry. 156:1990;442-443.
144. Shannon P.J., Leonard D., Kidson M.A. Fenfluramine and psychosis. Br Med J. 3:1974;576.
145. Bagri S., Reddy G. Delerium with manic symptoms induced by diet pills. J Clin Psychiatry. 59:1998;83.
146. Khan S.A., Speigel D.A., Jobe P.C. Psychotomimetic effects of anorectic drugs. Am Fam Physician. 36:1987;107-112.
147. Dietz A. Jr. Amphetamine-like reactions to phenylpropanolamine. JAMA. 245:1981;601-602.
148. Schaeffer C.B., Pauli M.W. Psychotic reaction caused by proprietary oral diet agents. Am J Psychiatry. 137:1980;1256-1257.
149. Ryan D.H., Kaiser P., Bray G.A. Sibutramine a novel new agent for obesity treatment . Obes Res. 3:(suppl 4):1995;553S-559S.
150. Bray G.A., Ryan D.H., Gordon D., Heidingsfelder S., Cerise F., Wilson K. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res. 1996;263-271.
151. Weintraub M. Long-term weight control study conclusions . Clin Pharmacol Therapeut. 51:1992;642-646.
152. Scheen AJ, Lefebvre PJ: Pharmacological treatment of obesity: present status. Int J Obes Relat Metab Disord 23(suppl 1):S47-S53, 1999.
153. Apfelbaum M., Vague P., Ziegler O., Hanotin C., Thomas F., Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet a randomized blinded trial of the efficacy and tolerability of sibutramine . Am J Med. 106:1999;179-184.
154. Guerciolini R. Mode of action of orilistat. Int J Obes Relat Metab Disord. 21:(suppl 3):1997;S12-S13.
155. Bray G.A. Obesity a time bomb to be defused . Lancet. 352:1998;160-161.
156. Gaal L.F.V., Broom J.I., Enzi G., Toplak H. Efficacy and tolerability of orlistat in the treatment of obesity a 6-month dose-ranging study. Orlistat dose-ranging study group . Eur J Clin Pharmacol. 54:1998;125-132.
157. Sjostrom L., Rissanen A., Anderson T., Boldrin M., Golay A., Koppeschaar H.P., Krempf M. Randomised placebo-controlled trial for orlistat for weight loss and prevention of weight gain in obese patients. Lancet. 352:1998;167-172.
158. McNeely W., Benfield P. Orlistat. Drugs. 56:1998;241-249.
159. Pierce NS ST, Macdonald IA, Tattersall RB: The effect of sibutramine and weight reduction on insulin sensitivity in obese type 2 diabetics. Int J Obes(Suppl 3):S669, 1998.
160. Zhi J., Melia A., Koss-Twardy S.G., Arora S., Patel I.H. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers. Pharmacology. 36:1996;152-159.
161. Melia A., Koss-Twardy S., Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol. 36:1996;647-653.
162. Hutton PA: A descriptive and correlational study of physical health, risk factors, and psychosicial variables among severely mentally ill veterans in a day treatment program. Salt Lake City, University of Utah, 1994.
163. Ayllon T. Intensive treatment of psychotic behavior by stimulus satiation and food reinforcement. Behav Res Ther. 21:1963;53-61.
164. Bernard J.L. Rapid treatment of gross obesity by operant techniques. Psychol Rep. 23:1968;663-666.
165. Harmatz M.G., Lapuc P. Behavior modification of overeating in a psychiatric population. JCCP. 32:1968;583-587.